Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 5.02
NAS:MYOS's Cash-to-Debt is ranked higher than
55% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. NAS:MYOS: 5.02 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:MYOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: No Debt Max: No Debt
Current: 5.02
Equity-to-Asset 0.80
NAS:MYOS's Equity-to-Asset is ranked higher than
79% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. NAS:MYOS: 0.80 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:MYOS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.17  Med: 0.87 Max: 0.96
Current: 0.8
0.17
0.96
Piotroski F-Score: 5
Altman Z-Score: 0.23
Beneish M-Score: -1.83
WACC vs ROIC
14.91%
-148.89%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -1447.46
NAS:MYOS's Operating Margin % is ranked lower than
95% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. NAS:MYOS: -1447.46 )
Ranked among companies with meaningful Operating Margin % only.
NAS:MYOS' s Operating Margin % Range Over the Past 10 Years
Min: -4642.42  Med: -332.79 Max: -128.6
Current: -1447.46
-4642.42
-128.6
Net Margin % -1458.81
NAS:MYOS's Net Margin % is ranked lower than
95% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. NAS:MYOS: -1458.81 )
Ranked among companies with meaningful Net Margin % only.
NAS:MYOS' s Net Margin % Range Over the Past 10 Years
Min: -5653.54  Med: -429.17 Max: -128.48
Current: -1458.81
-5653.54
-128.48
ROE % -90.17
NAS:MYOS's ROE % is ranked lower than
91% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. NAS:MYOS: -90.17 )
Ranked among companies with meaningful ROE % only.
NAS:MYOS' s ROE % Range Over the Past 10 Years
Min: -2665.24  Med: -117.33 Max: -88.51
Current: -90.17
-2665.24
-88.51
ROA % -71.11
NAS:MYOS's ROA % is ranked lower than
93% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. NAS:MYOS: -71.11 )
Ranked among companies with meaningful ROA % only.
NAS:MYOS' s ROA % Range Over the Past 10 Years
Min: -2600  Med: -80.95 Max: -45
Current: -71.11
-2600
-45
ROC (Joel Greenblatt) % -289.56
NAS:MYOS's ROC (Joel Greenblatt) % is ranked lower than
87% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. NAS:MYOS: -289.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:MYOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -371466.67  Med: -738.82 Max: -205.82
Current: -289.56
-371466.67
-205.82
3-Year Revenue Growth Rate -53.80
NAS:MYOS's 3-Year Revenue Growth Rate is ranked lower than
97% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. NAS:MYOS: -53.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:MYOS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 144.7
Current: -53.8
0
144.7
3-Year EBITDA Growth Rate -3.60
NAS:MYOS's 3-Year EBITDA Growth Rate is ranked lower than
72% of the 577 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. NAS:MYOS: -3.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:MYOS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41  Med: 121.05 Max: 530.5
Current: -3.6
-41
530.5
3-Year EPS without NRI Growth Rate -8.30
NAS:MYOS's 3-Year EPS without NRI Growth Rate is ranked lower than
70% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. NAS:MYOS: -8.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:MYOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -64.9 Max: 400
Current: -8.3
0
400
GuruFocus has detected 2 Warning Signs with Myos Rens Technology Inc $NAS:MYOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:MYOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MYOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:VRX » details
MYOS Corp is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue.

MYOS Corp was incorporated in the State of Nevada on April 11, 2007. The Company is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue. In February 2011, the Company acquired its platform dietary supplement product called MYO-T12. Its trademark includes FORTETROPIN. Its competition includes numerous nutritional supplement companies that are fragmented in terms of geographic market coverage, distribution channels and product categories.

Ratios

vs
industry
vs
history
PB Ratio 2.91
MYOS's PB Ratio is ranked higher than
50% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. MYOS: 2.91 )
Ranked among companies with meaningful PB Ratio only.
MYOS' s PB Ratio Range Over the Past 10 Years
Min: 0.93  Med: 3.38 Max: 16.26
Current: 2.91
0.93
16.26
PS Ratio 37.41
MYOS's PS Ratio is ranked lower than
91% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. MYOS: 37.41 )
Ranked among companies with meaningful PS Ratio only.
MYOS' s PS Ratio Range Over the Past 10 Years
Min: 4.15  Med: 19.08 Max: 465.12
Current: 37.41
4.15
465.12
Current Ratio 4.06
MYOS's Current Ratio is ranked higher than
71% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. MYOS: 4.06 )
Ranked among companies with meaningful Current Ratio only.
MYOS' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 4.06 Max: 27.24
Current: 4.06
0.03
27.24
Quick Ratio 2.49
MYOS's Quick Ratio is ranked higher than
64% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. MYOS: 2.49 )
Ranked among companies with meaningful Quick Ratio only.
MYOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 2.76 Max: 26.31
Current: 2.49
0.03
26.31
Days Inventory 900.52
MYOS's Days Inventory is ranked lower than
100% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. MYOS: 900.52 )
Ranked among companies with meaningful Days Inventory only.
MYOS' s Days Inventory Range Over the Past 10 Years
Min: 43.32  Med: 251.52 Max: 1919.9
Current: 900.52
43.32
1919.9
Days Sales Outstanding 1.09
MYOS's Days Sales Outstanding is ranked higher than
99% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. MYOS: 1.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.09  Med: 80.84 Max: 932.01
Current: 1.09
1.09
932.01
Days Payable 142.01
MYOS's Days Payable is ranked higher than
81% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. MYOS: 142.01 )
Ranked among companies with meaningful Days Payable only.
MYOS' s Days Payable Range Over the Past 10 Years
Min: 20.31  Med: 44.16 Max: 153.49
Current: 142.01
20.31
153.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.30
MYOS's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. MYOS: -17.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.3  Med: -24.1 Max: -8.4
Current: -17.3
-32.3
-8.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.77
MYOS's Price-to-Net-Cash is ranked higher than
57% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.85 vs. MYOS: 9.77 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MYOS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.28  Med: 6.81 Max: 34.02
Current: 9.77
2.28
34.02
Price-to-Net-Current-Asset-Value 4.39
MYOS's Price-to-Net-Current-Asset-Value is ranked higher than
71% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. MYOS: 4.39 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MYOS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.55  Med: 5.56 Max: 80.17
Current: 4.39
1.55
80.17
Price-to-Tangible-Book 4.09
MYOS's Price-to-Tangible-Book is ranked lower than
54% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. MYOS: 4.09 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MYOS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.48  Med: 5.22 Max: 81.01
Current: 4.09
1.48
81.01
Price-to-Median-PS-Value 1.95
MYOS's Price-to-Median-PS-Value is ranked lower than
81% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. MYOS: 1.95 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYOS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 1.06 Max: 19.51
Current: 1.95
0.26
19.51
Earnings Yield (Greenblatt) % -31.54
MYOS's Earnings Yield (Greenblatt) % is ranked lower than
92% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. MYOS: -31.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -34.71  Med: 0 Max: 739.87
Current: -31.54
-34.71
739.87

More Statistics

Revenue (TTM) (Mil) $0.34
EPS (TTM) $ -1.17
Beta1.68
Short Percentage of Float19.27%
52-Week Range $1.02 - 6.98
Shares Outstanding (Mil)5.85
» More Articles for MYOS

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Are you Qurr-ious? MYOS Rens Technology Inc. Launches Qurr Product Line Powered by Fortetropin®, an... Mar 13 2017
'Qurr' line of revolutionary muscle-health and muscle-building products in newly-enhanced form set... Mar 01 2017
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Feb 21 2017
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... Feb 14 2017
MYOS RENS Technology Inc. Adopts Shareholder Rights Plan Feb 14 2017
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation... Feb 07 2017
Key Catalyst That Could Send Biotechs Soaring in 2017: Today's Reports on MYOS RENS Technology and... Feb 06 2017
MYOS RENS Technology Inc. Announces $2,125,000 Registered Direct Offering Feb 03 2017
Dr. Robert Hariri, stem cell pioneer and chairman of MYOS RENS Technology, states that 'healthy... Jan 30 2017
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 23 2017
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Jan 11 2017
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Dec 22 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 25 2016
MYOS RENS TECHNOLOGY INC. Financials Nov 22 2016
MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016 Nov 18 2016
MYOS RENS TECHNOLOGY INC. Files SEC form 10-Q, Quarterly Report Nov 14 2016
MYOS RENS Announces Publication of Its Fortetropin(R) Human Clinical Trial Manuscript Sep 29 2016
MYOS RENS Announces Publication of Its Fortetropin(R) Human Clinical Trial Manuscript Sep 29 2016
MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer Sep 07 2016
MYOS RENS Technology Inc. Appoints Joseph Mannello as Interim Chief Executive Officer Sep 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)